Browse the evidence

The current evidence is insufficient to establish ingestion recommendations for protein hydrolysate supplementation.

Practitioners should be cautious in making specific recommendations for protein hydrolysate intake until more evidence is available.

The incidence of type 2 diabetes among non-operated patients with obesity was 11.7% during the follow-up period.

Non-operated obese patients have a high incidence of type 2 diabetes, highlighting the need for effective interventions.

The incidence of type 2 diabetes among gastric bypass patients was comparable to that of the general population.

Gastric bypass surgery can reduce diabetes risk to levels similar to those in the general population, indicating its effectiveness.

The percentage of total time spent on moderate to vigorous physical activity (MVPA) significantly decreased from 3.0% to 2.5% after the intervention.

Practitioners should be aware that dietary improvements may not correlate with increased physical activity among nurses.

The review identified a relative paucity of diet and physical activity interventions for nurses and highlighted a clear need for more and better-designed studies.

There is a need for practitioners to develop and evaluate more targeted interventions for nurses.

The study utilized a 2-way ANOVA with Tukey’s post hoc comparison to evaluate differences between groups.

The statistical methods indicate a rigorous approach to analyzing the data.

No significant changes were found in body mass (BM) between linear training (LT) and undulating periodization (UP) groups after 8 weeks.

Both training protocols did not lead to significant changes in body mass for untrained older adults.

No significant changes were found in fat mass (FM) between linear training (LT) and undulating periodization (UP) groups after 8 weeks.

Both training protocols did not lead to significant changes in fat mass for untrained older adults.

No significant changes were found in fat-free mass (FFM) between linear training (LT) and undulating periodization (UP) groups after 8 weeks.

Both training protocols did not lead to significant changes in fat-free mass for untrained older adults.

PA may not be a critical factor influencing weight maintenance in PWD.

Weight maintenance strategies for PWD may need to consider factors beyond just physical activity.

Alabama participants had more favorable scores for hedonic eating at baseline and maintained these scores at week 16 compared to Colorado participants.

Understanding hedonic eating can help tailor interventions to improve weight loss outcomes.

The three evaluated accelerometers provided estimates of total energy expenditure (TEE) differing significantly from TEE measured by doubly labeled water (DLW), with differences ranging from -690 to 220 kcal/d.

Practitioners should be cautious when using these accelerometers for TEE estimation as they may not provide fully accurate results.

Regression equations generated from accelerometer-assessed TEE accounted for 46-74% of the variability in DLW-measured TEE.

The accelerometers can provide a reasonable estimate of TEE variability, but should be used with caution.

Habitual sleep duration did not alter overfeeding-mediated body weight gain, fat gain, and fat distribution.

Sleep duration may not influence weight or fat gain during overfeeding.

The evidence supporting GLP-1RAs for treating PsO and PsA remains limited.

Further clinical research is needed to establish the efficacy and safety of GLP-1RAs for PsO and PsA.

High-dose canagliflozin (300 mg/day) is significantly associated with reduced sepsis risk versus control.

Practitioners may consider high-dose canagliflozin as a safer option regarding sepsis risk.

Treatment duration had minimal influence on primary outcomes.

Practitioners may not need to adjust treatment duration based on infection risk concerns.

The psychiatric side effects resolved with medication cessation.

Discontinuation of GLP-1 RAs may alleviate associated psychiatric symptoms.

Metabolomic subtypes have shown potential in guiding treatment selection for obesity.

Practitioners can consider metabolomic profiles to tailor obesity treatments.

Prolonged and unreasonable use of GLP-1 agonists may lead to undesirable effects.

Healthcare providers should monitor patients for potential adverse effects when using GLP-1 agonists long-term.

The mean four-month weight loss percentage was statistically lower in the compounded Semaglutide group (9.11%) compared to the pure Semaglutide group (9.87%).

Practitioners should be aware that compounded Semaglutide may result in slightly less weight loss compared to pure Semaglutide.

There are significant adverse effects associated with GLP-1 receptor agonists.

Healthcare providers should be aware of the potential adverse effects when prescribing GLP-1 receptor agonists.

There is potential for further applications of GLP-1 receptor agonists outside of type 2 diabetes management.

Further research may reveal additional therapeutic uses for GLP-1 receptor agonists, which could expand treatment options.

Integrating pharmacological, minimally invasive, and genetic strategies may enhance long-term weight management and metabolic outcomes.

Combining different treatment modalities may lead to better results for patients with obesity.